-
Innovation Ranking
NewInnovation Ranking – VYNE Therapeutics Inc
VYNE Therapeutics Inc (VYNE Therapeutics), is a late stage biopharmaceutical company. It is focused on the development and commercialization of serlopitant for the treatment of pruritus associated with dermatologic conditions such as psoriasis and prurigo nodularis, and for refractory chronic cough. The company's pipeline product candidate serlopitant, is a small molecule, highly selective NK1-R antagonist which reduces pruritus and refractory chronic cough symptoms. The company has licensing opportunities for development and commercialization of its pipeline product in all markets other...
-
Product Insights
Vitiligo – Drugs In Development, 2023
Global Markets Direct’s, ‘Vitiligo - Drugs In Development, 2023’, provides an overview of the Vitiligo pipeline landscape. The report provides comprehensive information on the therapeutics under development for Vitiligo, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Colitis – Drugs In Development, 2023
Global Markets Direct’s, ‘Colitis - Drugs In Development, 2023’, provides an overview of the Colitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Colitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Plaque Psoriasis (Psoriasis Vulgaris) – Drugs In Development, 2023
Global Markets Direct’s, ‘Plaque Psoriasis (Psoriasis Vulgaris) - Drugs In Development, 2023’, provides an overview of the Plaque Psoriasis (Psoriasis Vulgaris) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Plaque Psoriasis (Psoriasis Vulgaris), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Interstitial Lung Fibrosis – Drugs In Development, 2023
Global Markets Direct’s, ‘Interstitial Lung Fibrosis - Drugs In Development, 2023’, provides an overview of the Interstitial Lung Fibrosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Interstitial Lung Fibrosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Canocapavir in Hepatitis B
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Canocapavir in Hepatitis B report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Canocapavir in Hepatitis BDrug Details:Canocapavir (ZMH-1505R) is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – VYN-201 in Vitiligo
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - VYN-201 in Vitiligo report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.VYN-201 in VitiligoDrug Details:VYN-201 is under development for the treatment of eczema, rheumatoid arthritis,...
-
Company Profile
VYNE Therapeutics Inc – Company Profile
VYNE Therapeutics Inc (VYNE Therapeutics) is a clinical-stage biopharmaceutical company that develops proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory diseases. The company’s pipeline products include VYN201, VYN202 and FMX114 in the form of topical, inhalational and oral. Its VYN201 pipeline product treats nonsegmental vitiligo, rheumatological and lung diseases. The company’s VYN202 and FMX114 treat rheumatoid arthritis, systemic lupus erythematosus, ulcerative colitis (UC), crohn’s, multiple sclerosis (MS), myeloproliferative neoplastic disorders and atopic dermatitis. It develops drugs by using...
Add to Basket -
Company Profile
SSP Group PLC – Company Profile
SSP Group PLC (SSP) is a concession catering company that operates food and beverage outlets in concession locations such as airports, rail stations, and highways. It operates outlets under its own brands, international and local brands, and bespoke concepts, including Ritazza, Upper Crust, Levito, Camden Food Co, Cabin, Norges, Millie’s, Starbucks, Burger King, Micasa Cantina, Vyne, Soul Grain, Le Grand Comptoir, The Train Blue, Urban Crave, Nippon Ramen, Juniper & Co, Peets Coffee, Oster!a, and M&S. The company operates outlets...
Add to Basket -
Product Insights
Acne Vulgaris Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Acne Vulgaris – Drugs In Development, 2022, provides an overview of the Acne Vulgaris (Dermatology) pipeline landscape. Acne vulgaris is a chronic skin disease involving blockage and inflammation of pilosebaceous follicles. Symptoms include crusting of skin bumps, cysts, papules (small red bumps), scarring of the skin and redness around the skin eruptions. Risk factors include adolescence, hair gels or oil-based cosmetics, sports equipment such as helmet straps rubbing and occluding...